# Natco Pharma Q1 profit slumps 57% on lower Lenalidomide sales

2026-08-14T10:49:50+00:00 | Business & Economy | Indian Opinion Desk

Corroboration: 2 independent outlets

Natco Pharma's consolidated net profit fell 57% year-on-year to Rs 206.5 crore in the June quarter, driven by lower sales of generic cancer drug Lenalidomide, The Hindu reports. Total revenue dropped 43% to Rs 794.4 crore as international formulations revenue halved to Rs 477.1 crore from Rs 1,120.9 crore a year earlier. The board declared an interim dividend of Rs 1.5 per share, with payment starting August 26. Natco shares ended 5.23% lower on the BSE at Rs 902.40. Revenue from the base business and other segments such as APIs and crop health sciences rose, but could not offset the steep decline in Lenalidomide sales.

## Coverage

- ndtvprofit.com <https://www.ndtvprofit.com/markets/natco-pharma-q1-result-profit-falls-57-percent-yoy-to-rs-207-crore-revenue-down-45-percent-yoy-11909315>
- thehindu.com <https://www.thehindu.com/business/Industry/natco-pharma-q1-net-revenue-slump-on-lower-cancer-drug-sales/article71345441.ece>

Tags: generic pharma, Natco Pharma, profit fall, Q1 results, revenue decline
Canonical: https://indianopinion.org/natco-pharma-q1-profit-plunges-57-to-rs-207-crore/
License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources.
Cite: https://indianopinion.org/natco-pharma-q1-profit-plunges-57-to-rs-207-crore/#story-in-brief

Review state: restored archive article, accurate at time of publication, not offered to search indexes.